Ketamine Sedation and Hypoxia: A Quality Improvement Project to Reduce Respiratory Events Receiving Intervention.


Journal

The Journal of emergency medicine
ISSN: 0736-4679
Titre abrégé: J Emerg Med
Pays: United States
ID NLM: 8412174

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 07 10 2019
revised: 05 03 2020
accepted: 18 03 2020
pubmed: 15 4 2020
medline: 24 6 2021
entrez: 15 4 2020
Statut: ppublish

Résumé

Ketamine is a well-studied and safe medication used for procedural sedation in the pediatric emergency department (ED). However, in our ED and urgent care (UC), we had higher rates of respiratory events receiving intervention (REs) than has been reported nationally. A quality improvement (QI) project was initiated to address this problem with the following aim: during a 24-month period, we aimed to decrease REs during i.v. ketamine sedation from > 10% to < 6% in our network of EDs and UCs. Inclusion criteria included patients in our EDs and UCs who received i.v. ketamine for procedural sedation. We organized a multidisciplinary team to identify key drivers for the primary outcome (i.e., REs) and establish interventions. We based process measures on key interventions and utilized 2 Plan-Do-Study-Act (PDSA) cycles, which we evaluated with Shewhart P (provost) charts. Balancing measures included length of sedation, success of sedation, and length of stay. REs decreased from 11.4% to 4.9%; this rate was maintained for 12 months, starting 1 month after PDSA cycle 2 implementation. There was no difference in REs for length of stay, length of sedation, or success of sedation. Using QI methodology, we reduced and maintained rates of RE to < 6%. Due to the nature of the project, it is difficult to link one intervention to the reduction in REs; however, a significant shift occurred just after PDSA cycle 2 interventions. This project can give a guideline for interventions to improve the safety of pediatric ketamine sedations.

Sections du résumé

BACKGROUND BACKGROUND
Ketamine is a well-studied and safe medication used for procedural sedation in the pediatric emergency department (ED). However, in our ED and urgent care (UC), we had higher rates of respiratory events receiving intervention (REs) than has been reported nationally.
OBJECTIVE OBJECTIVE
A quality improvement (QI) project was initiated to address this problem with the following aim: during a 24-month period, we aimed to decrease REs during i.v. ketamine sedation from > 10% to < 6% in our network of EDs and UCs.
METHODS METHODS
Inclusion criteria included patients in our EDs and UCs who received i.v. ketamine for procedural sedation. We organized a multidisciplinary team to identify key drivers for the primary outcome (i.e., REs) and establish interventions. We based process measures on key interventions and utilized 2 Plan-Do-Study-Act (PDSA) cycles, which we evaluated with Shewhart P (provost) charts. Balancing measures included length of sedation, success of sedation, and length of stay.
RESULTS RESULTS
REs decreased from 11.4% to 4.9%; this rate was maintained for 12 months, starting 1 month after PDSA cycle 2 implementation. There was no difference in REs for length of stay, length of sedation, or success of sedation.
CONCLUSIONS CONCLUSIONS
Using QI methodology, we reduced and maintained rates of RE to < 6%. Due to the nature of the project, it is difficult to link one intervention to the reduction in REs; however, a significant shift occurred just after PDSA cycle 2 interventions. This project can give a guideline for interventions to improve the safety of pediatric ketamine sedations.

Identifiants

pubmed: 32284229
pii: S0736-4679(20)30150-5
doi: 10.1016/j.jemermed.2020.03.014
pii:
doi:

Substances chimiques

Ketamine 690G0D6V8H

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

864-873

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Alexandria J Wiersma (AJ)

Department of Pediatric Emergency Medicine, Children's Hospital Colorado, Aurora, Colorado; University of Colorado, School of Medicine, Aurora, Colorado.

Benjamin Bernier (B)

Department of Pediatric Emergency Medicine, Children's Hospital Colorado, Aurora, Colorado.

Jan Leonard (J)

Department of Pediatric Emergency Medicine, Children's Hospital Colorado, Aurora, Colorado; University of Colorado, School of Medicine, Aurora, Colorado.

Debra Faulk (D)

Department of Pediatric Emergency Medicine, Children's Hospital Colorado, Aurora, Colorado; University of Colorado, School of Medicine, Aurora, Colorado.

Michael DiStefano (M)

Department of Pediatric Emergency Medicine, Children's Hospital Colorado, Aurora, Colorado; University of Colorado, School of Medicine, Aurora, Colorado.

Joseph Wathen (J)

Department of Pediatric Emergency Medicine, Children's Hospital Colorado, Aurora, Colorado; University of Colorado, School of Medicine, Aurora, Colorado.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH